A PMHNP in an outpatient psychiatric clinic is treating a 34-year-old man with comorbid generalized anxiety disorder and opioid use disorder. The patient has declined medication-assisted treatment with buprenorphine on multiple occasions, stating he is "not ready to quit" but acknowledges that his opioid use has led to two nonfatal overdoses in the past year. He continues to attend psychiatric appointments for his anxiety and has maintained a therapeutic relationship with the PMHNP for six months. At today's visit, the PMHNP considers how to address the patient's ongoing opioid use within a harm reduction framework. Which of the following approaches best reflects harm reduction principles in this clinical context?